Atzemian Natalia, Mohammed Shafeeq, Di Venanzio Ludovica, Gorica Era, Costantino Sarah, Ruschitzka Frank, Paneni Francesco
Center for Translational and Experimental Cardiology (CTEC), Zurich University Hospital, University of Zurich, Zurich, Switzerland.
Cardiology Department of Research and Education, University Heart Center, Zurich, Switzerland.
Epigenomics. 2025 May;17(7):463-474. doi: 10.1080/17501911.2025.2489921. Epub 2025 Apr 21.
Epigenomics is a rapidly emerging field that has gathered significant attention as a "non-genetic determinant" implicated in the manifestation of non-communicable diseases. Exploring epigenetic modifications provides novel insights into the management of cardiometabolic disease (CMD). Epigenetics signatures are influenced by environmental stressors such as air pollution, toxins, and urban noises as well as by established cardiovascular risk factors including smoking, sedentary lifestyle, obesity, and diabetes. Understanding how epigenetic alterations lead to CMD as well as inter-individual differences in epigenetic makeup could unveil new molecular targets and new epi-drugs to be employed for precision medicine approaches in the growing population of patients with cardiometabolic disease to reduce cardiovascular risk. Herein, we provide an overview of the latest advancements in epigenetic mechanisms implicated in CMD and possible therapeutic opportunities.
表观基因组学是一个迅速兴起的领域,作为一种与非传染性疾病表现相关的“非遗传决定因素”,已受到广泛关注。探索表观遗传修饰为心血管代谢疾病(CMD)的管理提供了新的见解。表观遗传特征受到空气污染、毒素和城市噪音等环境应激源的影响,也受到吸烟、久坐不动的生活方式、肥胖和糖尿病等既定心血管危险因素的影响。了解表观遗传改变如何导致CMD以及个体间表观遗传组成的差异,可能会揭示新的分子靶点和新的表观遗传药物,用于越来越多的心血管代谢疾病患者的精准医学方法,以降低心血管风险。在此,我们概述了与CMD相关的表观遗传机制的最新进展以及可能的治疗机会。